OpenLB
Open Library of Bioscience
Advanced Search
PeerJ
2023;11 e16313.

Association of triglyceride-glucose index with the risk of prostate cancer: a retrospective study.

Tianqi Li, Yijie Zhou, Jinru Wang, Songtao Xiao, Yajun Duan, Caihong Li, Yi Gao, Hengqing An, Ning Tao
Author Information
  1. Tianqi Li: School of Public Health, Xinjiang Medical University, Urumqi, China.
  2. Yijie Zhou: School of Public Health, Xinjiang Medical University, Urumqi, China.
  3. Jinru Wang: School of Public Health, Xinjiang Medical University, Urumqi, China.
  4. Songtao Xiao: School of Public Health, Xinjiang Medical University, Urumqi, China.
  5. Yajun Duan: School of Public Health, Xinjiang Medical University, Urumqi, China.
  6. Caihong Li: School of Public Health, Xinjiang Medical University, Urumqi, China.
  7. Yi Gao: School of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, China.
  8. Hengqing An: Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  9. Ning Tao: Department of Epidemiological Statistics, School of Public Health, Xinjiang Medical University, Urumqi, China.
PMID: 37953784 DOI: 10.7717/peerj.16313

Abstract

Background: Prostate cancer is the most common malignancy in men, and its incidence is increasing year by year. Some studies have shown that risk factors for prostate cancer are related to insulin resistance. The triglyceride-glucose (TyG) index is a marker of insulin resistance. We investigated the validity of TyG index for predicting prostate cancer and the dose-response relationship in prostate cancer in relation to it.
Objective: To investigate the risk factors of TyG index and prostate cancer prevalence.
Methods: This study was screened from the First Affiliated Hospital of Xinjiang Medical University and included 767 people, including 136 prostate cancer patients in the case group and 631 healthy people in the control group. The relationship between TyG index and the risk of prostate cancer was analyzed by one-way logistic regression, adjusted for relevant factors, and multi-factor logistic regression analysis was performed to further investigate the risk factors affecting the prevalence of prostate cancer. ROC curves and Restricted Cubic Spline were established to determine the predictive value and dose-response relationship of TyG index in prostate cancer.
Results: Blood potassium (OR = 0.056, 95% CI [0.021-0.148]), total cholesterol (OR = 1.07, 95% CI [0.792-1.444]) and education level (OR = 0.842, 95% CI [0.418-1.697]) were protective factors for prostate cancer, alkaline phosphatase, age, LDL, increased the risk of prostate cancer (OR = 1.016, 95% CI [1.006-1.026]) (OR = 139.253, 95% CI [18.523-1,046.893] (OR = 0.318, 95% CI [0.169-0.596]); TyG index also was a risk factor for prostate cancer, the risk increased with TyG levels,and persons in the TyGQ3 group (8.373-8.854 mg/dL) was 6.918 times (95% CI [2.275-21.043]) higher than in the Q1 group,in the TyGQ4 group (≥8.854) was 28.867 times of those in the Q1 group (95% CI [9.499-87.727]).
Conclusion: TyG index may be a more accurate and efficient predictor of prostate cancer.

Keywords

Hyperinsulinemia Insulin resistance Low-density lipoprotein Prostate cancer Total cholesterol Triglyceride-glucose (TyG) index

References

  1. Neoplasia. 2022 Feb;24(2):86-97 [PMID: 34954451]
  2. Front Oncol. 2022 May 02;12:891352 [PMID: 35586488]
  3. CA Cancer J Clin. 2018 Jan;68(1):7-30 [PMID: 29313949]
  4. Obes Rev. 2015 Jan;16(1):1-12 [PMID: 25407540]
  5. Am J Hypertens. 2022 Feb 1;35(2):132-141 [PMID: 34599797]
  6. J Natl Cancer Inst. 2003 Jan 1;95(1):67-71 [PMID: 12509402]
  7. Prostate Int. 2013;1(1):16-22 [PMID: 24223397]
  8. Diabetes Res Clin Pract. 2011 Sep;93(3):e98-e100 [PMID: 21665314]
  9. Lancet Child Adolesc Health. 2020 May;4(5):359-369 [PMID: 32333883]
  10. Clin Cancer Res. 2010 Jul 15;16(14):3539-47 [PMID: 20606036]
  11. Health Policy. 2011 Feb;99(2):97-106 [PMID: 20708815]
  12. J Cell Physiol. 2021 Jul;236(7):5253-5264 [PMID: 33368314]
  13. Acta Diabetol. 2012 Dec;49(6):465-72 [PMID: 22965469]
  14. Int J Oncol. 2001 Apr;18(4):683-7 [PMID: 11251161]
  15. J Natl Cancer Inst. 2009 Sep 16;101(18):1272-9 [PMID: 19700655]
  16. Oman Med J. 2011 Mar;26(2):109-13 [PMID: 22043395]
  17. Crit Rev Oncol Hematol. 2006 May;58(2):124-45 [PMID: 16387509]
  18. Asian Pac J Cancer Prev. 2014;15(2):1031-3 [PMID: 24568446]
  19. Indian J Urol. 2010 Oct;26(4):502-6 [PMID: 21369380]
  20. Front Oncol. 2021 Mar 11;11:585388 [PMID: 33777737]
  21. PLoS One. 2014 Feb 28;9(2):e90430 [PMID: 24587359]
  22. Am J Physiol Endocrinol Metab. 2022 Jul 1;323(1):E2-E7 [PMID: 35635329]
  23. Endocr Connect. 2021 Nov 05;10(11):1420-1427 [PMID: 34636743]
  24. Eur J Cancer Prev. 2022 Nov 1;31(6):554-557 [PMID: 35352690]

MeSH Term

Male
Humans
Retrospective Studies
Insulin Resistance
Prostatic Neoplasms
Alkaline Phosphatase
Glucose

Chemicals

Alkaline Phosphatase
Glucose
Journal Article

Word Cloud

Created with Highcharts 10.0.0cancerprostateTyGindexrisk95%CIgroupOR=factors[0resistancerelationship0Prostateyearinsulintriglyceride-glucosedose-responseinvestigateprevalencestudypeoplelogisticregressioncholesterol1increased854timesQ1Background:commonmalignancymenincidenceincreasingstudiesshownrelatedmarkerinvestigatedvaliditypredictingrelationitObjective:Methods:screenedFirstAffiliatedHospitalXinjiangMedicalUniversityincluded767including136patientscase631healthycontrolanalyzedone-wayadjustedrelevantmulti-factoranalysisperformedaffectingROCcurvesRestrictedCubicSplineestablisheddeterminepredictivevalueResults:Bloodpotassium056021-0148]total07792-1444]educationlevel842418-1697]protectivealkalinephosphataseageLDL016[1006-1026]139253[18523-1046893]318169-0596]alsofactorlevelspersonsTyGQ38373-8mg/dL6918[2275-21043]higherTyGQ4≥828867[9499-87727]Conclusion:mayaccurateefficientpredictorAssociationcancer:retrospectiveHyperinsulinemiaInsulinLow-densitylipoproteinTotalTriglyceride-glucose

Similar Articles

Cited By